Infliximab therapy for 2 patients with Vogt-Koyanagi-Harada syndrome.
To report the authors' experience using infliximab to treat 2 patients with Vogt-Koyanagi-Harada disease (VKH). Interventional case series. Medical records of the 2 patients were reviewed. After starting infliximab intravenous infusions, 5 mg/kg, both patients experienced rapid improvement in their VKH disease, and were able to taper and discontinue prednisone without disease recurrence for the several-month follow-up period. Infliximab may be effective treatment for VKH, and spares patients the side effects of corticosteroids and conventional immunosuppressive drugs.